Mascha Binder, Head of Medical Oncology in the Universitätsspital Basel (USB), shared a post on LinkedIn about a recent article she and her colleagues authored:
“I am very happy to share that our anti-IGLV3-21-R110 BiTE is now published!
The IGLV3-21-R110 mutation defines a particularly aggressive form of chronic lymphocytic leukemia (CLL). Because this change is found only in malignant B cells and not in healthy ones, it offers a unique opportunity for targeted therapy.
In collaboration with my fantastic team at the Department of Biomedicine and collaborators in Kiel, New York, and Freiburg, we developed a bispecific antibody (BiTE) designed to recognize this mutation and engage T cells against CLL cells carrying it. This is an exciting step toward mutation-directed immunotherapy in CLL and shows how precision oncology can be extended beyond genetic diagnostics to antibody-based treatments.
Congratulations to Claudia Fischer for her first Basel paper!
And a special thank you to Matthias Peipp, Heinz Läubli, Obinna Chijioke and Nicholas Chiorazzi for making this project possible!”
Title: IGLV3-21R110-directed bispecific antibodies activate T cells and promote killing in a high-risk subset of chronic lymphocytic leukemia
Authors: Claudia Fischer, Shih-Shih Chen, Johanna Nimmerfroh, Anne Eugster, Simon Stücheli, Christoph Schultheiß, Corinne Widmer, Dominik Heim, Benjamin Kasenda, Jakob Passweg, Sebastian Kobold, Lukas Egli, Nicolò Coianiz, Obinna Chijioke, Nicholas Chiorazzi, Marie Follo, Heinz Läubli, Matthias Peipp, Mascha Binder
Read the Full Article in haematologica.
More posts featuring CLL on OncoDaily.